Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154)

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Perambakam, Supriya ^a   Xie, Hui ^b   Edassery, Seby ^c   Peace, David J ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CANCER VACCINE; CREATININE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HLA A2 ANTIGEN; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; PSA146 154; TETRAMER; UNCLASSIFIED DRUG; HORMONE; PEPTIDE; PEPTIDE FRAGMENT; PROSTATE SPECIFIC ANTIGEN (146 154); PROSTATE-SPECIFIC ANTIGEN (146-154);

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DELAYED HYPERSENSITIVITY; DIFFERENTIAL DISPLAY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HORMONE SENSITIVE PROSTATE CANCER; HUMAN; IMMUNE RESPONSE; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; BIOSYNTHESIS; CHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; RISK FACTOR; VACCINATION;

AGED; CANCER VACCINES; HLA-A2 ANTIGEN; HORMONES; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; VACCINATION;

EID: 79952203202     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/473453     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA-Cancer Journal for Clinicians 2009 59 4 225 249
2. Pronzato P., Rondini M., Hormonotherapy of advanced prostate cancer Annals of Oncology 2005 16 4 iv80 iv84
3. Kantoff P., Higano C. S., Berger E. R., Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC) Proceedings of the Genitourinary Cancers Symposium of the American Society of Clinical Oncology 2010. Abstract #8
4. Xue B. H., Zhang Y., Sosman J. A., Peace D. J., Induction of human cytotoxic T (Pubitemid 27088114)
5. Perambakam S., Xue B. H., Sosman J. A., Peace D. J., Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer Cancer Immunology, Immunotherapy 2002 51 5 263 270 (Pubitemid 34810707)
6. Perambakam S., Hallmeyer S., Reddy S., Mahmud N., Bressler L., DeChristopher P., Mahmud D., Nunez R., Sosman J. A., Peace D. J., Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide Cancer Immunology, Immunotherapy 2006 55 9 1033 1042 (Pubitemid 43800718)
7. Lau R., Wang F., Jeffery G., Marty V., Kuniyoshi J., Bade E., Ryback M. E., Weber J., Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma Journal of Immunotherapy 2001 24 1 66 78 (Pubitemid 32103309)
8. Irizarry R. A., Bolstad B. M., Collin F., Cope L. M., Hobbs B., Speed T. P., Summaries of Affymetrix GeneChip probe level data Nucleic acids research 2003 31 4 e15
9. Meidenbauer N., Harris D. T., Spitler L. E., Whiteside T. L., Generation of PSA-reactive effector cells after vaccination with a PSA- based vaccine in patients with prostate cancer Prostate 2000 43 2 88 100 (Pubitemid 30220611)
10. Higano C. S., Schellhammer P. F., Small E. J., Burch P. A., Nemunaitis J., Yuh L., Provost N., Frohlich M. W., Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 2009 115 16 3670 3679
11. Kantoff P. W., Schuetz T. J., Blumenstein B. A., Glode L. M., Bilhartz D. L., Wyand M., Manson K., Panicali D. L., Laus R., Schlom J., Dahut W. L., Arlen P. M., Gulley J. L., Godfrey W. R., Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer Journal of Clinical Oncology 2010 28 7 1099 1105
12. Thomas-Kaskel A. K., Zeiser R., Jochim R., Robbel C., Schultze-Seemann W., Waller C. F., Veelken H., Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival International Journal of Cancer 2006 119 10 2428 2434 (Pubitemid 44546968)
13. Gulley J. L., Arlen P. M., Madan R. A., Tsang K. Y., Pazdur M. P., Skarupa L., Jones J. L., Poole D. J., Higgins J. P., Hodge J. W., Cereda V., Vergati M., Steinberg S. M., Haiabi S., Jones E., Chen C., Parnes H., Wright J. J., Dahut W. L., Schlom J., Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunology, Immunotherapy 2010 59 5 663 674
14. Palucka A. K., Ueno H., Fay J. W., Banchereau J., Taming cancer by inducing immunity via dendritic cells Immunological Reviews 2007 220 1 129 150 (Pubitemid 350045575)
15. Disis M. L., Bernhard H., Shiota F. M., Hand S. L., Gralow J. R., Huseby E. S., Gillis S., Cheever M. A., Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 1996 88 1 202 210 (Pubitemid 26230688)
16. Disis M. L., Gooley T. A., Rinn K., Davis D., Piepkorn M., Cheever M. A., Knutson K. L., Schiffman K., Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines Journal of Clinical Oncology 2002 20 11 2624 2632 (Pubitemid 34575634)
17. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Medicine 1998 4 3 328 332 (Pubitemid 28144092)
18. Thurner B., Haendle I., Rder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., Von Den Driesch P., Brcker E. B., Steinman R. M., Enk A., Kmpgen E., Schuler G., Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma Journal of Experimental Medicine 1999 190 11 1669 1678 (Pubitemid 30002348)
19. Banchereau J., Palucka A. K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K. M., Bhardwaj N., Pineiro L., Steinman R., Fay J., Immune and clinical responses in patients with metastatic melanoma to CD34 progenitor-derived dendritic cell vaccine Cancer Research 2001 61 17 6451 6458 (Pubitemid 32783251)
20. Timmerman J. M., Czerwinski D. K., Davis T. A., Hsu F. J., Benike C., Hao Z. M., Taidi B., Rajapaksa R., Caspar C. B., Okada C. Y., Van Beckhoven A., Liles T. M., Engleman E. G., Levy R., Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 2002 99 5 1517 1526 (Pubitemid 34533020)
21. Peoples G. E., Gurney J. M., Hueman M. T., Woll M. M., Ryan G. B., Storrer C. E., Fisher C., Shriver C. D., Ioannides C. G., Ponniah S., Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients Journal of Clinical Oncology 2005 23 30 7536 7545 (Pubitemid 46291817)
22. Haralambieva I. H., Dhiman N., Ovsyannikova I. G., Vierkant R. A., Pankratz V. S., Jacobson R. M., Poland G. A., 2 ′-5′ -Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine Human Immunology 2010 71 4 383 391
23. Tsai M. H., Cook J. A., Chandramouli G. V. R., DeGraff W., Yan H., Zhao S., Coleman C. N., Mitchell J. B., Chuang E. Y., Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation Cancer Research 2007 67 8 3845 3852 (Pubitemid 46762172)
24. Maia C. J. B., Socorro S., Schmitt F., Santos C. R. A., Characterization of oligoadenylate synthetase-1 expression in rat mammary gland and prostate: effects of 17 -estradiol on the regulation of OAS1g in both tissues Molecular and Cellular Biochemistry 2008 314 1-2 113 12